{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:57:30Z","timestamp":1792634250880,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Fibrosing mediastinitis (FM) is an uncommon fibroinflammatory condition without established or effective medical therapies. Infiltrating B lymphocytes are commonly present, and progressive fibrosis compromises mediastinal structures, including blood vessels and airways, resulting in significant morbidity and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the benefits and side effects of rituximab in patients with progressive and symptomatic FM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We treated 22 patients (median age, 35 yr; range, 15\u201368 yr; 45% female) with metabolically active, progressive FM with rituximab on an off-label basis. Additionally, patients were administered pneumocystis and antifungal prophylaxis when immunosuppressed with rituximab. Modeling of longitudinal treatment response based on changes in relative lesion volume from baseline was performed retrospectively using functional data analysis, and time-to-event modeling was performed to estimate treatment response rates based on a\u2009&amp;gt;30% reduction in pretreatment volume. The primary endpoints were lack of disease progression and change in mediastinal lesion volume on computed tomography (evaluated retrospectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No patient experienced disease progression after rituximab therapy. Median clinical follow-up was 42 months (range, 7\u201394 mo) and imaging follow-up 21 months (range, 7\u201362 mo). A total of 82% of patients had confirmed histoplasmosis-associated FM. After rituximab treatment, a 49.6% (95% confidence interval, 17.5\u201364.4%) mean estimated decrease in pretreatment lesion volume was observed at 24 months. The estimated objective treatment response rate was 47.9% (95% confidence interval, 26.7\u201370.3%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This observational study suggests that rituximab is a well tolerated and potentially effective therapy in a cohort of patients with symptomatic and progressive FM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202405-533oc","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:22:15Z","timestamp":1722964935000},"page":"1533-1541","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":8,"title":["A Retrospective Evaluation of the Treatment Effects of Rituximab in Patients with Progressive and Symptomatic Fibrosing Mediastinitis"],"prefix":"10.1093","volume":"21","author":[{"given":"Cyril","family":"Varghese","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Department of Critical Care Medicine, Mayo Clinic, Phoenix, Arizona; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Radiology"},{"name":"Department of Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Eiken","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Edell","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[{"name":"Department of Immunology"},{"name":"Division of Pulmonary Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2026012203190882800_bib1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/0003-4975(92)91025-5","article-title":"Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis","volume":"54","author":"Lagerstrom","year":"1992","journal-title":"Ann Thorac Surg"},{"key":"2026012203190882800_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00005792-197205000-00008","article-title":"Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis","volume":"51","author":"Goodwin","year":"1972","journal-title":"Medicine (Baltimore)"},{"key":"2026012203190882800_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-5223(19)42725-6","article-title":"Granulomatous and fibrous mediastinitis. A review and analysis of 180 cases","volume":"57","author":"Schowengerdt","year":"1969","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026012203190882800_bib4","first-page":"207056","article-title":"Histopathologic overlap between fibrosing mediastinitis and IgG4-related disease","volume":"2012","author":"Peikert","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2026012203190882800_bib5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1378\/chest.104.4.1276","article-title":"Bilateral pleural effusion due to mediastinal fibrosis induced by radiotherapy","volume":"104","author":"Morrone","year":"1993","journal-title":"Chest"},{"key":"2026012203190882800_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7326\/0003-4819-94-3-331","article-title":"A large urban outbreak of histoplasmosis: clinical features","volume":"94","author":"Wheat","year":"1981","journal-title":"Ann Intern Med"},{"key":"2026012203190882800_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00005792-198809000-00002","article-title":"Mediastinal fibrosis complicating histoplasmosis","volume":"67","author":"Loyd","year":"1988","journal-title":"Medicine (Baltimore)"},{"key":"2026012203190882800_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MD.0b013e318237c8e6","article-title":"Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response","volume":"90","author":"Peikert","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2026012203190882800_bib9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1513\/AnnalsATS.201610-782RL","article-title":"Bronchoscopic management of airway compression due to fibrosing mediastinitis","volume":"14","author":"Kern","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203190882800_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1747-0803.2010.00387.x","article-title":"Results of intravascular stent placement for fibrosing mediastinitis","volume":"5","author":"Ferguson","year":"2010","journal-title":"Congenit Heart Dis"},{"key":"2026012203190882800_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0003-4975(92)90069-G","article-title":"Clinical manifestation of mediastinal fibrosis and histoplasmosis","volume":"54","author":"Mathisen","year":"1992","journal-title":"Ann Thorac Surg"},{"key":"2026012203190882800_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2214\/AJR.11.7319","article-title":"Imaging of granulomatous fibrosing mediastinitis","volume":"199","author":"McNeeley","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"2026012203190882800_bib13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.crad.2007.03.002","article-title":"Computed tomography findings in fibrosing mediastinitis","volume":"62","author":"Devaraj","year":"2007","journal-title":"Clin Radiol"},{"key":"2026012203190882800_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026012203190882800_bib15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","article-title":"Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab","volume":"47","author":"McGonagle","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2026012203190882800_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1164\/rccm.201407-1258LE","article-title":"Targeting B lymphocytes in progressive fibrosing mediastinitis","volume":"190","author":"Westerly","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203190882800_bib17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1378\/chest.117.2.482","article-title":"Mediastinal fibrosis is associated with human leukocyte antigen-A2","volume":"117","author":"Peebles","year":"2000","journal-title":"Chest"},{"key":"2026012203190882800_bib18","first-page":"599","article-title":"The etiology of discrete splenic and hepatic calcifications in an endemic area of histoplasmosis","volume":"39","author":"Okudaira","year":"1961","journal-title":"Am J Pathol"},{"key":"2026012203190882800_bib19","volume-title":"Common Terminology Criteria for Adverse Events, version 5.0","author":"U.S. Department of Health","year":"2017"},{"key":"2026012203190882800_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/JTO.0b013e3182199be2","article-title":"Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer","volume":"6","author":"Force","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2026012203190882800_bib21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ejrad.2013.02.018","article-title":"Exploring intra-and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals","volume":"82","author":"Zhao","year":"2013","journal-title":"Eur J Radiol"},{"key":"2026012203190882800_bib22","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1097\/MJT.0000000000001039","article-title":"Rituximab to treat fibrosing mediastinitis\u2013 associated recurrent hemoptysis","volume":"27","author":"Flora","year":"2020","journal-title":"Am J Ther"},{"key":"2026012203190882800_bib23","doi-asserted-by":"crossref","first-page":"A3433","DOI":"10.1016\/j.chest.2023.07.2232","article-title":"Metabolic response of fibrosing mediastinitis to rituximab therapy","volume":"164","author":"Osondu","year":"2023","journal-title":"Chest"},{"key":"2026012203190882800_bib24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1533\/66013942\/annalsats_21_11_1533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/11\/1533\/66013942\/annalsats_21_11_1533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:19:21Z","timestamp":1769069961000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/11\/1533\/8380737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202405-533oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"2024-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}